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Abstract: Sequences of the genomes of all-important bacterial pathogens of man, plants,
and animals have been completed. Still, it is not enough to achieve complete information of
all the mechanisms controlling the biological processes of an organism. Along with all
advances in different proteomics technologies, proteomics has completed our knowledge of
biological processes all around the world. Proteomics is a valuable technique to explain the
complement of proteins in any organism. One of the fields that has been notably benefited
from other systems approaches is bacterial pathogenesis. An emerging field is to use
proteomics to examine the infectious agents in terms of, among many, the response the
host and pathogen to the infection process, which leads to a deeper knowledge of the
mechanisms of bacterial virulence. This trend also enables us to identify quantitative
measurements for proteins extracted from microorganisms. The present review study is an
attempt to summarize a variety of different proteomic techniques and advances. The sig-
nificant applications in bacterial pathogenesis studies are also covered. Moreover, the areas
where proteomics may lead the future studies are introduced.
Keywords: bacterial pathogenesis studies, drug resistance, virulence, pathogen, proteomics
Introduction
Proteins are responsible for the biological functions that are dictated by genes in
most cases.1 The vast protein interaction networks control the strange cellular
functions mainly. It is not possible to elaborate on these networks by merely
relying on a single protein or a few proteins.2 One of the ways to explain the
biological systems of microorganisms in a large scale is proteomics. This
technique provides us with information as to abundances, post-translational
modifications, localization, interactions, and changes.3 The sustained develop-
ment of different proteomic technologies determines the capacity of proteomics
to deal with major issues in the microbial field. There is a need for qualitative
and quantitative studies in this field.4 Other systems approaches have also
notable benefits for microbial pathogenesis. There is an emerging trend of
using proteomics to study infectious agents.5 Using proteomic analysis to
study protein profiles of bacterial pathogenesis is one of the main approaches
to study proteins and interactions of the host-pathogen to find a deeper knowl-
edge of dysregulations in infection disorders,6 reveal bacterial resistance and
virulence mechanisms,7 and significant new targets for future drug discovery.8
The immense potential of proteomic technologies to achieve a deeper insight
into pathogenesis and develop therapeutic techniques is undeniable.
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Pathogenic microorganisms like viruses, bacteria, or
fungi9 are responsible for infectious diseases and represent
serious health risks for man, animals, and plants.10 In spite
of great works to develop new strategies to fight and
prevent infections, the risk of newly emerging infectious
diseases is undeniable.11 The key point of infectious dis-
ease researches is a deeper insight into the functional
interface between pathogenic microbes and their host
cells.12 Still, our knowledge of exact molecular adhesion,
invasion, and replication is quite limited.13 This lack of
knowledge is an obstacle to develop new diagnostic and
therapeutic strategies.14 Additionally, the complicated
interaction between host and pathogens is controlled by
hundreds to thousands of proteins from both sides.15 Most
of the research work in this field has concentrated on
determining the characterization of individual bacterial
virulence factors and their interacting host targets using
traditional genetic and biochemical approaches.16
However, these studies fail to elaborate on the complicated
multifactorial nature of host-pathogen interactions.17 On
the other hand, systems-level analyses give us a panoramic
perspective of the functional host-pathogen interplay,
which is significant improvement progress from the tradi-
tional reductionism-dominant research.18 Therefore, tran-
scriptomic studies have been around for several years and
still, there is a great desire for measuring the final gene
products, proteins. This is because of the poor correlation
between mRNA and protein levels due to extensive post-
transcriptional regulations.
One of the most important and interesting aspects of
life is the ongoing interaction between hosts and
pathogens.19 These interactions take place throughout the
long years of evolution; so that the hosts create defense
mechanisms to handle pathogenic invasions and pathogens
circumvent these new defense mechanisms.20 Thanks to
adaptation processes, some hosts can co-exist with or even
have the benefit of pathogens. However, many pathogens
still function as etiological agents for many life-
threatening human diseases.21 Therefore, having a clear
understanding of host-pathogen interactions has led to the
introduction of different means to prevent and treat infec-
tion-induced diseases. This study discusses the advantages
and drawbacks of a gel-free/label-free proteomic technique
along with introducing the potential application of proteo-
mics in bacterial pathogen studies. In addition, the avail-
ability of proteomics approaches to uncover host-pathogen
protein interaction networks, changes in the composition,
and the organization of the host cell proteome are
explained.
Applications of Proteomic
Techniques in Bacteria
The metabolic aspects of an organism on a global scale are
the subject matter of proteomic studies. Through this,
large-scale proteomic technologies are developed
prosperously.5 Proteomic studies enable us to identify
genome or/and measure proteins from microorganisms in
a quantitative manner.22 Researcher keeps developing pro-
teomic techniques so that there are wide range methods
and applications available.23 Needless to say, proteomic
technologies provide great potential to shed light on patho-
genesis and develop new therapeutic techniques based on
these insights. The latest studies have conducted reference
proteomes for different bacterial pathogens and direct the
future studies that need baseline proteomes for performing
comparison.24 Valuable information is provided by this
technological platform as to signal transduction, adher-
ence, and microbial-host interactions pertinent to bacterial
pathogenesis.
Protein Identification
Measuring protein using the 2D gel electrophoresis
method is the standard way for proteomic analysis.25 The
original separation technology (2-DE) can separate pro-
teins based on their isoelectric point and molecular weight
using SDS-polyacrylamide gel electrophoresis in the first
and second dimensions, respectively.26 In addition, to have
sensitivity, covalent labeling of proteins with fluorescent
Cy-dyes is used before separation. This technique is
known as 2D difference gel electrophoresis (DIGE) can
achieve higher quality and number of protein spots and
gives more reliable gel matching.27,28 On the other hand,
these gel-based techniques are not sensitive enough to
small quantities of proteins and they have limited pro-
teome resolution.29 Another disadvantage of these
approaches is their poor performance in detecting different
types of post-translational modifications of a single protein
that causes crosstalk among signal pathways.30 While one
of the disadvantages of membrane proteomics based on the
gel-free approach is the solubilization of membranous
proteins, which is because of different optimum
condition,31 the volume of data available for membrane
protein repertoire is growing.32 Several bacterial studies
including Mycobacterium tuberculosis,33 Scheffersomyces
Khodadadi et al Dovepress
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stipitis,34 and Staphylococcus aureus35 have used a gel-
free technique, which further indicates the potential of this
method by the identification of a far larger number of
proteins. Gel-based and gel-free protein quantification,
which are used as complementary approaches, are effec-
tive techniques to analyze the regulatory mechanisms uti-
lized by bacteria. In Klebsiella pneumoniae as a successful
example, the P13K-mediated vesicular transport was iden-
tified by the combination of both approaches.36 Thus, it is
essential for studies on plant stress responses to carefully
select the proteomic approaches and cellular events that
should be resolved by the approach.
Quantitative Proteomics
Both relative and absolute protein quantification are sup-
ported by mass spectrometry (MS)-based quantification
strategy.37 Metabolic in vivo labeling techniques like
SILAC (stable isotope labeling with amino acids in cell
culture) and15 N labeling makes it possible to measure smal-
ler measurement bias.38 A chemical in vitro labeling methods
like the ICAT (isotope-coded affinity tag),18 O labeling, TMT
(tandemmass tags) and iTRAQ (isobaric tags for relative and
absolute quantification) can be used for static samples such
as clinical samples.39,40 Another identical strategy called
isotope-coded protein label (ICPL) labels both N-termini
and lysine side chains and is used at the protein level.41
Currently, TMT and iTRAQ are the most commonly used
techniques for labeling as it can be used for differential
quantification of different protein post-translational
modifications.42 The iTRAQ-based differential proteomics
of total proteins using a Rhodococcus sp. BAP-1induced by
fluoranthene showed a decrease in the abundance of
cytochrome ubiquinol oxidase subunit, NAD(P) transhydro-
genase subunit alpha, 5-methyltetrahydropteroyltrigluta-
mate-homocysteine methyltransferase; still, there was an
increase in the abundance of NADPH-dependent FMN
reductase, 30S ribosomal protein S2, and
S-ribosylhomocysteinase.43–45 A technique to find differen-
tial bacterial proteomic profiling of Staphylococcus aureus46
is the iTRAQ-based strategy; still, limitations of label-based
techniques create problems in experimental design to com-
pare samples so that only a few studies have used iTRAQ-
based strategy in bacteria. These studies have beenmainly on
the stress response, which needs comparison among multiple
conditions.47 The use of the iTRAQ-based technique to sub-
cellular compartments has the limitation of expensive
reagents and the complicated process of preparing
samples.48 On the other hand, label-free quantitation is free
of any limitations as to the number of samples for
analysis.49,50 With label-free quantitation based on MS/MS,
liquid chromatography (LC) is used to separate the digested
peptides and transferred to a first mass spectrometer (MS1)
where the chromatograms depicting signal intensities are
obtained to measure the abundance of each peptide.51 The
peptide ions are adopted for deeper fragmentation in MS2
and determine the parent ion.52 Label-free LC-MS/MS gives
us the chance for wide quantification of proteins.53 Thanks to
advantages like easy sample preparation that is done faster in
gel-free, label-free quantification allows accumulation of
large volume of data in S. aureus proteomics, revealing
central responses of S. aureus exposure to cold stress. In
the case of subcellular proteomics in S. aureus, changes in
the specific factors indicate the importance of citric acid-
related signal transduction,54 which controls the early stage
of the bacteria’s response to stress. Still, the unsolved pro-
blem in this method is how to optimize LC-MS chromato-
gram alignment for accurate quantification.55 Many
platforms use MS/MS scan times or base peak information
to align chromatograms.56 The merit of gel-free, label-free
proteomics is in the ease of sample preparation and the
acceptance for data production.57 That to the large-scale
data analysis of accumulated data on protein abundance58 it
is possible to elucidate biological processes that aremissed in
small-scale experiments (Table 1).
Proteomics Methods to Provide
Mechanistic Insights in Infectious
Diseases
Infection by different pathogens that are intrinsic to our
ecosystem is the main reason for human disease and
death worldwide.59 An interesting aspect of life is the
ongoing interaction between hosts and pathogens.20
Researchers have concentrated on creating a molecular
picture of pathogen infection and spread in an attempt to
control the prevalence of infectious disease and develop
better treatments for diseases.60 Therefore, to find more
about pathogen-host interactions is a driving force for
the event of suggests that to stop and treat infection-
induced diseases.61 Over the past years, omic
approaches have been introduced as effective tools in
basic, translational, and clinical analysis to examine
biological pathways effective in pathogen replication,
host response, and disease progression. Proteomics
tries to study the protein complement of biological sys-
tems and it has managed to show the discovery and
Dovepress Khodadadi et al
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Table 1 Different Techniques in Quantitative Proteomic with the Associated Strengths and Limitations
Techniques Methods Strengths Limitations Representative
References
2DE Separation on a gel of the protein
content of a sample in two
dimensions according to mass and
charge, gels are stained and spot
intensities in samples are compared
among different gels
Simple Involves large amount of
sample
[131]
Robust Low throughput
Suitable for MS analysis Poor recovery of hydrophobic
proteins
High inter-gel variability
2-DIGE Measuring three samples per gels,
each of them is labelled with a
different fluorescent dye, and the
intensities of each gel spot for each
sample are measured at a
wavelength specific for the label
Multiplexing Expensive Cy dyes [28]
Better quantitation Poor recovery of hydrophobic
proteins
Minimal gel to gel variation Difficulty in separating low
molecular weight compounds
Gel-free methods
SILAC Direct isotope labeling of cells High throughput Only suitable for tissue
culture models
[38]
Differential expression pattern Robust Costly reagents
A vital technique for secreted
pathways and secreted proteins in
cell culture Comprising labeling of
the N-terminus and side chain amine
groups of proteins
Sensitive and simple Not applicable to tissue
sample
ICAT Chemical isotope labeling for
quantitative proteomics comparing
relative protein abundance between
two samples.
Selectively isolates peptide Post-translational
modification information is
frequently lost; cannot
identify proteins with less
than eight cysteines
[39]
Compatible with any amount of
protein
Complexity of the peptide mixture
is reduced
Large ICAT label (≈500 Da)
Protein
microarrays
Binding of a targeted protein in one Hight throughput Synthesis of many different
probes
[44]
Sample to spotted probes on a
“forward” microarray; conversely,
binding of specific probes to a
targeted protein in spotted samples
on a “reverse” microarray;
detection of bound proteins by
direct labelling or by labelled
secondary antibodies
Biomarker identity Necessary; Identity or class of
targeted proteins must be
known Limited to detection
of proteins targeted by the
probes
ITRAQ Isobaric tagging of peptides Applicable to versatile samples Expensive reagents [42]
4 or 8 analysis samples can be
quantified
Better quantitation Incomplete labeling
Simultaneously; The method is
based on the covalent labeling of the
N-terminus and sidechain amines of
peptides from protein digestions
with tags of varying mass
Multiplexing Involves high amount of
sample
(Continued)
Khodadadi et al Dovepress
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understanding of pathogen-host interactions.6 This is the
outcome of every improved proteomic technology that
gives us sensitive protein detection and quantification
tools. In addition, it increases awareness inside the bio-
logical science community and promotes using these
approaches in innovative ways.
Table 1 (Continued).
Techniques Methods Strengths Limitations Representative
References
SELDI-TOF Selected part of a protein mixture is
Bound to a specific chromatographic
surface and the rest washed away
High throughput Unsuitable for high molecular
weight
[51]
MS Direct application of whole sample Proteins; Limited to detection
of bound proteins; Lower
resolution and mass accuracy
Small amount of starting material
MALDI-TOF Application of a protein mixture
onto
High throughput Need for sample fractionation
of complex
[50]
MS A gold plate; desorption of proteins
from the plate by laser energy and
measurement of the protein masses;
comparison of peak intensities
between multiple samples
Samples; More starting
material needed for sample
fractionation; Unsuitable for
high molecular weight
proteins
LC-MS/MS Separation of a mixture of peptides
(resulting from protein digestion
with trypsin) by one-, two- or three-
dimensional LC and measurement of
peptide masses by MS-MS
Direct identification of several
hundred proteins per sample by MS-
MS of peptides
Low throughput [53]
Time consuming
Detection by MS-MS often
not comprehensive;
Complicating comparison of
different samples
ICPL After labeling of up to four different
proteome states the samples can be
combined and the complexity
reduced by any separation method
currently employed in protein
chemistry
High-throughput quantitative
proteome profiling on a global scale;
able to detect to detect post-
translational modifications and
protein isoforms; applicable to
Isotopic effect of deuterated
tags interferes with retention
time of the peptides
[41]
Protein like tissue extracts or body
fluids
SRM A powerful tandem mass
spectrometry method that can be
used to monitor target peptides
within a complex protein digest with
capability to multiplex the
measurement of many analytes in
parallel
Highly sensitive, quantitatively
accurate and highly reproducible
Detection and quantification
of non- abundant proteins;
Sensitivity is not comparable
to immunological assays;
[45]
Quantification of post-translational
modifications;
Limited broad scale
application because of
difficulty in generating high-
quality
Protein detection is relatively rapid
Enables detection of non-abundant
proteins
SRM assay
Label-free Measuring the relative
concentrations of peptide analytes
within two or more samples;
require the least sample
preparation; as a tool to validate
preliminary quantitative proteomics
experiments
Avoids labeling Not suitable for low abundant
proteins
[49]
Involves less amount of sample Incomplete digestion may
introduce error
Higher proteome coverage Multiplexed analysis not
possible in one experiment;
High throughput
instrumentation
Dovepress Khodadadi et al
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Intracellular Host-Pathogen Protein–
Protein Interactions
The past ten years have witnessed a great contribution to
comprehending host-pathogen interaction in the cellular
life cycle of a pathogen by proteomic techniques.62
Notably, the hyphenation of traditional analytical and bio-
chemical techniques based on mass spectrometry has led
to proteomic approaches that examine different aspects of
the host-pathogen relationship.11 Given that before repro-
ducing to propagate, intracellular pathogens should pass
through the host defenses, pathogen proteins interact with
host proteins to either suppress or hijack the normal host
protein functions.6 Identification of those protein–protein
interactions (PPIs) is essential, among many, for under-
standing the biology of infection; in addition, it can be
used for new targets in treatments against human patho-
gens. In this study, the proteomics strategies that can be
used to discover pathogen-host interaction networks, intact
protein complexes, or direct interactions are reviewed.
Furthermore, their strengths, limitations, and future pro-
mising directions in the context of finding out infectious
diseases are discussed.
Building Host-Pathogen Protein Interaction
Networks
Immunoaffinity purification along with mass spectrometry
(IP-MS) are of the methods that have received the widest
attention in pathogen-host interaction studies.6 To isolate
a protein in IP-MS, an antibody raised against the endo-
genous protein or epitope-tagging the protein of interest
and using an antibody against that epitope are the
options.63 Therefore, the protein of interest and co-
isolated interacting proteins are identified using MS. As
to host-pathogen associations, the main advantages of IP-
MS are the fact that experiments can be done in pertinent
cellular model systems and the context of viral infection so
that unbiased detection of PPIs is possible.64 In the case of
bacteria, IP-MS is utilized to detect interactions between
effector proteins secreted by intracellular Salmonella and
host proteins. Also, SILAC quantification is used to exam-
ine the specificity of interactions.65 The multiplexing cap-
ability of TMT is not used in host-pathogen PPI studies
yet; still, it allows for the simultaneous measurement of
different infection time points along with negative controls
to examine the specificity of the interactions detected.20
Specific interactions of histone deacetylases by label-free
methods and the relative stability of these interactions by
SILAC were both determined using the combined
analysis.66 Thus, these approaches can be expanded to
find valuable information as to dynamic host-pathogen
interactions.
The fact that infections can cause significant changes in
protein abundances in a cell and that the background of non-
specific associations can differ completely from the one
observed in an uninfected cell are key issues in pathogen-
host interaction studies.67 Thus, controlling isolations should
be done in the same biological context under study. There are
many computer algorithms available that utilize the data
provided by control and experimental isolations to filter
false-positive PPIs.68 One of them is the significance analysis
of interactome (SAINT).69 This algorithm allocates interac-
tion specificity scores to filter low-confidence interactions.
Informatics approaches can also be employed to achieve
a more refine identified interactions. For example, by creat-
ing extra controls for non-specific associations, like the con-
taminant repository for affinity purification (CRAPome).70
A recently developed database for HSV-1 interactions,
HVint, creates an integrated resource of HSV-1 protein inter-
actions. It uses using evolutionary conservation of herpes-
virus proteins to further predict additional interactions.71
Thus, once a list of interactions is ready, these PPIs can be
visualized within a functional network. This facilitates iden-
tifying the underlying biology in host-pathogen interactions.
These results are indicative of the fact that further studies can
improve the use of quantitative proteomics for comprehend-
ing infectious diseases.
Analysis of Intact Protein Complexes
To perform fully different functions, proteins usually exist
simultaneously in distinct protein complexes. Though IP-
MS gives us inventories of protein interactions, it averages
together several protein complexes that host the same
protein of interest.72 Moreover, information about the
ratio of associations in a complex is lost in the absence
of fractionation and analysis. Top-down MS analyses
where proteolytic digestion is not needed for analyzing
proteins, can facilitate obtaining information about an
intact macromolecule or multiprotein advanced.73
Additionally, it protects each of the non-covalent interac-
tions and consequently the post-translational state of the
proteins inside the complex. Moreover, the technique is
mostly used to individual infective agent proteins, like the
hepatitis c virus pore protein p7,74 and pathogenic com-
plexes reconstituted in vitro (eg the Norwalk virus-like
particles).75 Still, top-down MS is not used to study host-
pathogen complexes. Moreover, Top-down MS was
Khodadadi et al Dovepress
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combined with ion mobility separation to find more about
different forms of a multiprotein complex.76 Therefore,
top-down MS appears to be a reliable tool for studying
host-pathogen protein complexes.
Detecting Direct Interactions
The yeast two-hybrid (Y2H) assay is one of the
classic techniques for detecting direct PPIs.77 The
Enterohemorrhagic E. coli (EHEC) is not an intracellular
pathogen; however, it has a close intracellular interaction
with the host, as it injects 39 proteins into the host cytosol
at least. The Y2H was also used to explain direct PPIs
between EHEC and thus the human host cells.78
A drawback of Y2H is that it has a relatively high false-
positive rate, which is due to the non- physiological
expression of proteins in cellular compartments where
they are not commonly expressed. Moreover, because
pathogen proteins are expressed beyond the context of an
infection, many potentially relevant interactions might be
missed. Along with MS, Hydrogen/deuterium exchange is
another in vitro method to find the interacting regions of
two proteins.79 Besides, progresses made in search algo-
rithms designed for cross-linking MS studies have added
to their simple use.80 Along with the identification of
direct PPIs, crosslinkers are capable of stabilizing weaker
or transient interactions and improving their identification;
still, this increases non-specific associations. A study used
those cross-linking tools and computational development
to create a large dataset of direct interactions between
human lung cells and Acinetobacter baumannii. Results
have shown that a subset of that was useful for bacterial
invasion.81 Thereby, the examination of RNA-protein
interactions by MS can improve our knowledge of post-
transcriptional regulation processes that may have an
important pathogenic infection.
Pathogen-Induced Proteome Alterations
in Time and Space
A central role is played by the production, degradation,
and spatial reorganization of proteins for the replication of
pathogens.82 Usually, the pathogen causes changes in the
levels of specific host proteins required for replication. By
global alterations in the proteome organization, the host
also reacts to the pathogen invasion, which is critical for
mounting effective defenses.83 Thereby, these studies give
us a deeper insight into the control of specific time points
of infection and the required subcellular compartment
reorganization.
Temporal Analysis of the Infected Cellular Proteome
Thanks to the provision of perfectly established protocols
and the latest MS instrumentation, temporal proteome
alterations are now accepted approaches.84,85 A reliable
was to characterize pathways controlled by the infectious
agent and key protein effective in pathogenicity is temporal
protein analyses.85 Depended on cellular metabolism,
viruses have attained several mechanisms such as control-
ling energy production and lipid synthesis.86 Several studies
have been performed on broad alterations in proteins meta-
bolism regulation of human-relevant viruses, like the
recently re-emerged Chikungunya virus,87 human cytome-
galovirus (HCMV),88 flaviviruses,89 and hepatitis C virus
(HCV).90 Additionally, some of these changes are tempo-
rally controlled; for instance, HCV regulation of glycolysis
proteins happened only early in infection, whereas proteins
used in lipid metabolism were increased continuously.90
These proteome alterations are also capable of correlating
with pathogenicity as it was reported by temporal proteomic
studies on different influenza strains.91 Notably, there is
a relationship between regulation of specific proteins by
the emerging and extremely virulent H7N9 influenza virus
and its increased cytopathic effects.92 Because infections
cause a wide range of proteome alterations, further studies
have focused on individual pathogenic proteins.
According to proteomic studies that introduce the RTA
protein coded by Kaposi’s sarcoma-associated virus
(KHSV), which triggers lytic reactivation, known
ARID3B as a number protein vital to initiate lytic
replication.93 Based on this knowledge, which was used
by cell culture systems, temporal proteomic analyses of
the infection process have been successfully used for
in vivo studies in animal models challenged with viruses
and bacterium.94 Based on these findings, this technology
makes it possible to carry out the in-depth characterization
of specific organelles when infection appears so that there
would be no need to eliminate the necessity of doing
organelle enrichment and fractionation.
Spatial Cellular Proteome Organization During
Infection
It is possible to determine infection-induced changes in
protein abundances using proteome analyses on entire
cells; however, the spatial information needed to under-
stand proteome organization and characterize molecular
mechanisms of pathogen infection is not provided.95,96
To measure protein abundances in different parts of
infected and clean cells we can tag cells by SILAC and
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fractionated technique, which minimizes technical varia-
bility in the fractionation steps.97 Another option is to keep
the uninfected and infected samples separate throughout
fractionation so that quantification can be done through
label-free approaches or isobaric tags.98 These alternatives
bring the advantage of less limitation in the variety of
samples so that analyzing multiple fractions and infection
time points becomes possible. Changes that are induced by
infection on the cell surface proteome prove the dynamic
role of the plasma membrane proteome in the transport of
metabolites with the extracellular space,100 intracellular
and living thing signaling,99 and cell attachment during
infection.101 According to proteomic studies, viral-induced
alterations play a role in the mitochondria biogenesis,
oxidative phosphorylation, and the electron transport
chain in return.102 By integrating quantitative proteomics
and live-cell microscopy, the present study introduces
a wide range of alterations in organelle composition and
form and distinct protein translocations between secretory
organelles needed for the production of infectious particles
are mentioned.88 Moreover, the integration of strategies to
follow the dynamic localization of proteins inside the
cell103 gives us more information about the spatial reorga-
nization of the cell proteome when an infection takes
place.
Pathogen-Induced Regulation of Protein
Post-Translational Modifications
By altering protein interactions, stability, activity, and sub-
cellular localization, post-translational modifications
(PTMs) controls protein functions. Thereby, PTM regula-
tion has a key role in the progression and results of infec-
tion on either host or pathogen proteins.104 Cellular
landscape studies on PTMs and their pathogen-induced
regulation have yielded valuable insights into host-
pathogen interactions.
Diverse Forms of Post-Translational Modifications
are Relevant in the Context of Infection
Different PTMs are efficient means of controlling signal
transduction, virulence and regulatory processes on bacter-
ial proteins like phosphorylation, acetylation, methylation,
and deamidation.105 The PTMs are a key process in the
life cycle of bacteria so that they can modulate main
virulence factors and they are attractive targets for novel
therapies.106 Finding these PTMs in bacteria is a technical
challenge as they are not easy to discover given that the
modifications usually exist at low levels of abundance.107
To compensate this, specific enrichment strategies that
target certain PTMs are used to lower peptide complexity
and increase the chance of finding and characterizing; for
instance, immunoaffinity enrichment is a standard way for
lysine-acetylated peptides.108 In addition, identical enrich-
ment strategies are used to find phosphorylation events on
serine, threonine, and tyrosine (S/T/Y) amino acid
residues.109
Novel lysine-acetylation events in virulence factors help
host immune response evasions like chitin-binding protein,
a serine protease, exotoxin A, and hemolysin. This means
that lysine acetylation events in Pseudomonas aeruginosa
affect the mechanisms pertinent to virulence.110 Results
have shown that cysteine phosphorylation in S. aureus
help in controlling bacterial virulence and vancomycin
resistance.111 The authors used high-resolution MS to
explain in a site-specific fashion, that cysteine phosphoryla-
tion events took place in different proteins so that many of
them are global regulators that control important biological
processes.
MS as a Tool to Study Host and Pathogen Protein
PTMs
Post-translational modifications can be observed in cells,
and many of them are dynamically regulated when an
infection occurs. Therefore, global PTM analyses can be
done using proteomic methods.112 Selected global PTM
mapping is concentrated on specific types of modifications
and it has been done for various pathogenic agents such as
bacteria,112 fungi,113 protozoa,114 and viruses115 to detect
and measure SUMOylations, phosphorylations, acetyla-
tions, and histone modifications.116 The main tool for
PTM discovery experiments is the selective enrichment
of specific proteins or PTMs and then identifying the
modified peptides.117 Normally, this enrichment is done
by antibodies against the PTM or protein or by a resin that
can enrich a class of PTMs using the chemical
properties.118 Along with these discovery-driven experi-
ments, targeted MS/MS methods including selected reac-
tion monitoring (SRM) or parallel reaction monitoring
(PRM) are tools for sensitive monitoring of PTMs on
proteins of interest.119 Despite their well-recognized
value that makes accurate quantification of low abundance
PTMs possible,120 pathogen infection studies have not
used these approaches frequently; still, they can be used
more commonly in the future to widen our knowledge of
proteome regulation during infection. Moreover, there is
a lack of systematic examination of different types of
Khodadadi et al Dovepress
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PTMs and regulation of them as to time and space in
infectious contexts.121 This is true for PTMs that are
critical regulators of protein functions like phosphoryla-
tion, ubiquitination, and acetylation along with emerging
PTMs of which our knowledge about their impact on
protein functions like malonylation, succinylation, and
lipoylation is limited.122 Moreover, for the identified
PTMs, the detailed effect of many of these modifications
either in uninfected or infected cells is unclear.
Multi-Omics Integration for the Study of
Host-Pathogen Interactions
There are several uses forMulti-omic approaches like deter-
mining the coding capability of pathogens, identifying key
virulence factors, and outlining the responsibilities of the
host to pathogenic infection.123 Proteomics is also added to
transcriptomic analyses to have a better annotation of infec-
tious agent genomes,124 provide experimental proof for
genes, delineate intergenic events, and purify the limits of
available gene models of pathogens.125 Although, it is not
easy to analyze the data of these varieties of experiments,
there are procedural platforms to facilitate future proteoge-
nomic analysis in pathogens.126 Proteomics, glycopeptido-
mics, and glycomics were used to find glycosylation sites
and glycoform distribution in different influenza strains.127
This approach has enabled us to determine the glycosyla-
tion patterns of selective pressure obligatory by host
immune factors, that influence the strain antigenicity and
virulence.
While new omics methods are being introduced
every day, it is important to integrate them with alternative
omics approaches to achieve higher levels of data that
might improve pathogenic research, like as integrating
host and infectious agent PTMs128 or subcellular location
data.88 A key point in multi-omics studies is that access to
informatics platforms that may be accustomed to access
and visualize the data such as Immunet.129 Thereby, pro-
viding these resources is essential for generating data-
driven hypotheses for future pathogenic. While IP-MS is
designed for studying protein complexes within
bacteria,130 its use has remained limited to study in vivo
pathogen-host cell protein interactions and their dynamic
regulation throughout infection.131 Proteomic approaches
that support protein microarrays, complement IP-MS
approaches and demonstrate interesting opportunities for
high-throughput screening of infectious agent interactions.
By recognizing protein-encoding plasmid DNA and then
translating it into exploitation noncellular expression sys-
tems merely before using the sample, the nucleic acid
Programmable Protein Array (NAPPA) technology outper-
forms the common pitfalls that influence microarrays
imprinted with purified proteins.132 When used together,
there would be no need to use antibodies or generate
recombinant pathogenic strains. This can be specifically
advantageous for basic analysis investigation into the
molecular networks of infectious agent interactions.
Proteomics Methods to Provide
Mechanistic Insights in Bacterial
Antibiotic Resistance
Human health is growingly threatened by bacterial patho-
gens as the number and distribution of antibiotic-resistant
bacterium and the rate of discovery of recent antimicro-
bials dwindles is increasing.133 Since using antibiotics to
fight infectious diseases, microorganisms have started to
fight back. Using resistance mechanisms microbes can by-
pass and survive the action of antibiotic drugs.134 There
are several strategies to find these mechanisms and asso-
ciated in-progress efforts to lower the steady increase in
the number of treatment failures due to multi-drug-
resistant microbes.135 Proteomics is one of the key tools
in this area of research. They have key roles in realizing
the molecular mechanisms of bacterial pathogenesis and in
distinctive disease outcome determinants.136 The physical
associations find by proteomics lead to tools to develop
pathogen-specific treatment strategies that lower the
spread of antibiotic resistance.137 After the recent fast
advances in whole-genome sequencing, proteomic tech-
nologies are used extensively to examine microbial gene
expression.138 Therefore, proteomics has emerged as
a reliable tool to review bacteria. There are many com-
parative proteomic studies on bacteria-resistant to develop
different antibiotics and some are mentioned in the follow-
ing sections (Figure 1; Table 2).
Cell Wall-Acting Antibiotics
Beta-Lactams
Beta-lactams antibiotics are generally categorized as penicil-
lin, cephalosporin, carbapenems, monobactam, beta-
lactamase inhibitors, and other minor categories.139 The
beta-lactams halt the synthesis and/or stability of the cell
envelope, which results in the biogenesis of cell-wall and
loss of selective permeability and osmotic integrity in return
and finally bacterial cell death.140 Beta-lactam antibiotics
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resistance is one of the commonly studied resistance based
on proteomics methods.141 Antibiotic hydrolyzing proteins is
the main resistance mechanisms to beta-lactam antibiotics,
which is also known as beta-lactamases.142 There are other
major mechanisms like imbalance in transport proteins such
as efflux pumps and porins and alteration in the penicillin-
binding protein targets.143 The growing trend of using anti-
biotics has resulted in the rate of some key resistance strains
like methicillin-resistant Staphylococcus aureus, penicillin-
resistant Streptococcus pneumoniae, and extended-spectrum
beta-lactamase (ESBL),144 as well as carbapenemase-
producing Enterobacteriaceae, Pseudomonas aeruginosa,
and Acinetobacter baummanni.145 The findings by proteomic
researchers give us deep insights into ampicillin-resistant
Pseudomonas aeruginosa, where novel porins are involved
in resistance.146 Studies on the resistance to piperacillin/
tazobactam in Escherichia coli have shown that the expres-
sion of porin OmpX was lowered and the expression of TolC
increased.147 Wither regard to the penicillin-tolerant Gram-
positive Streptococcus pyogenes, overexpression of murein
metabolism proteins and general alteration of bacterial phy-
siology are reported.148 Studies on methicillin-resistant
S. aureus have revealed changes in cell physiology and
overexpression of catalase and superoxide dismutase.149
Alanine dehydrogenase has been found effective in antibiotic
resistance.150 Studies on inner membrane fraction
of carbapenem-resistant A. baumanni have revealed
a relationship with beta-lactamase AmpC and OXA-51 pro-
duction along with metabolic enzymes, elongation factor Tu,
and ribosomal proteins.151
Glycopeptide
Glycopeptide vancomycin functions through stopping pep-
tidoglycan synthesis. It binds to the DAla-DAla terminus
of the nascent peptidoglycan and therefore blocks the
correct synthesis.152 Substitution of the DAla residue
from peptidoglycan termini by D-lactose or D-Serine, in
Enterococcus spp., was found to be the key mechanism of
resistance to vancomycin.153 In addition, in S. aureus,
a more complicated scenario was proposed with diverse
enzymes and gene clusters implicated in vancomycin-
resistance. Resistant strains like vancomycin-resistant
Staphylococcus aureus (VRSA) and vancomycin-resistant
enterococci (VRE) are of main clinical concern.154
Wang et al155 studied vancomycin-resistant Enterococcus
faecalis and investigated a reference strain (V583) and
a clinical isolate (V309) with and without vancomycin.
The results supported the regulation of the proteins
involved in vancomycin resistance functions, virulence
factors, stress, metabolism, translation, and conjunction.
Ramos et al156 determined the proteomic profiles of van-
comycin-resistant E. faecium SU18 strain treated and not
Figure 1 Overview of bacterial antibiotic resistance mechanisms. Antibiotics target essential bacterial processes and structures to inhibit cell growth and/or causing cell
death. The major cellular targets for antibiotics include DNA replication (eg, fluoroquinolones), protein synthesis (eg aminoglycosides), cell wall integrity (eg, penicillins) and
folic acid metabolism (eg, sulfonamides).
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Table 2 Proteomic Studies of Bacterial Antibiotic Resistance Mechanisms
Antibiotic Pathogens Physiological effects Proteome Analysis Representative
References
Cell wall
Vancomycin Enterococcus
faecium
Vancomycin resistance proteins increased;
metabolism-related proteins decreased
2-DE and LC-MS/MS [156]
Piperacillin/
tazobactam
Escherichia coli Bacterial virulence, antibiotic resistance, DNA
protection, and multidrug efflux pump expression
associated with resistance
2D-flurorescence difference
gel and electrophoresis (2D-
DIGE)
[147]
Carbapenem Acinetobacter
baumannii
Beta-lactamases, energy, and protein production
enzymes are upregulated;
2D-DIGE [151]
OmpW and surface antigen downregulated
Penicillin Streptococcus
pyogenes
Growth phase, stress, and fatty acid biosynthesis
(FAB) proteins expression altered
Two dimensional gel
electrophoresis (2-DE) and
tandem mass spectrometry
[148]
Cell membrane
Colistin Escherichia coli Outer membrane proteins, chaperones, protein
biosynthesis factors and metabolic enzymes
2-DE and LC-MS/MS [167]
Daptomycin Staphylococcus
aureus
Differences in biofilm formation proteins, cell wall-
associated targets
iTRAQ and IPG-isoelectric
focusing with LC-MS
[161]
Protein synthesis
Kanamycin Escherichia coli Outer membrane protein expression altered.
Identification of novel membrane MipA protein
involved in antibiotic resistance
2-DE and LC-MS/MS [197]
Tetracycline Acinetobacter
baumannii
Outer membrane proteins decreased expression in
membrane and increased secretion
2-DE/MS-MS and 1-DE/LC/MS-
MS
[190]
Linezolid Streptococcus
pneumoniae
Metabolism and transport of carbohydrates involved
in resistance to linezolid
2-DE and iTRAQ [187]
Protein synthesis
Chloramphenicol Burkholderia
thailandensis
Overexpression of efflux pump systems associated
with resistance
SDS-PAGE electrophoresis and
LC-MS/MS
[183]
Erythromycin Streptococcus
pneumoniae
Glyceraldehyde-3-phosphate dehydrogenase
upregulation in resistant strain
2-DE and LC-MS/MS [201]
DNA synthesis
Fluoroquinolones Pseudomonas
aeruginosa
Overexpression of ATP-binding component of ATP
binding cassette (ABC)
2-DE and LC-MS/MS [206]
Metronidazole Clostridium
difficile
RecA, ferric uptake regulator (Fur), putative nitro
reductases and altered expression of stress-related
proteins
iTRAQ and 2D-LC-MS/MS [212]
RNA synthesis
Rifampicin Brucella
abortus
Alterations in several metabolic processes and
secretion mechanisms
2-DE and LC-MS/MS [217]
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treated with vancomycin. 14 proteins are differentially
expressed in SU18. Proteins that played a role in the
vancomycin resistance mechanisms demonstrated an
increase in the presence of vancomycin; while there was
a decrease in metabolism-related proteins, which results in
compensatory effects. Notably, the proteomic profile of
a group of heterogeneous vancomycin-intermediate
Staphylococcus aureus (hVISA) vancomycin susceptible
S. aureus has been compared.157 At first, five upregulated
proteins in hVISA were detected and only one of them
supported by real-time quantitative reverse transcription
PCR (qRT-PCR) – ie the protein encoded by the isaA
gene involved in cell wall biogenesis.
Cell Membrane-Acting Antibiotics
Daptomycin
A new mechanism of action that is demonstrated by
daptomycin is a cyclic lipopeptide antibiotic.158 This
agent functions on the cell wall membrane structure
and it is synthesized through binding to the cell mem-
brane using a calcium-dependent mechanism. This
results in the efflux of potassium ions of the bacterial
cells.159 This process results in bacterial cell death in.160
Daptomycin is active against Gram-positive bacteria and
it is clinically used to treat intense infections by these
organisms (MRSA bacteremia, skin and soft tissue
infections, endocarditis, and VRE infections,).7 Based
on comparative proteomics profiles in the daptomycin-
susceptible S. aureus strain and the daptomycin-resistant
S. aureus strain 701, there is a differential abundance of
proteins in different functional categories, such as
cell wall-associated targets and biofilm formation
proteins.161 In addition, LiaI and LiaH proteins caused
(429-fold) by daptomycin, using the proteomic approach
of a daptomycin-susceptible B. subtilis strain W168 in
presence of daptomycin treatment of sublethal amount
(1 μg/mL).162 The removal of the response regulator
LiaR controls the expression of liaIH in daptomycin-
resistant E. faecalis and reversed resistance to daptomy-
cin. This leads to hypersusceptibility to daptomycin.163
Thereby, it can be concluded that LiaR is the main
regulator that protects cell membranes against diverse
antimicrobial agents, by regulating the expression of
different genes like liaH gene. Thus, the study showed
that several proteins of different functional categories,
including cell wall-associated targets, had different
expressions.
Colistin
As an antimicrobial peptide, Colistin interacts with the
bacterial outer membrane, by replacing bacterial counter
ions in the lipopolysaccharide (LPS).164 Hydrophobic
and hydrophilic regions interact with the cytoplasmic
membrane as a detergent and make the membrane
solubilized.165 The main common mechanisms of resis-
tance to colistin are modifications to LPS.166 Li et al167
studied proteins in mcr-1-mediated colistin-resistant and -
susceptible Escherichia coli to achieve a deeper insight
into the colistin resistance mechanism. They showed that
the substrate phosphoethanolamine (PEA) for mcr-1 that
mediated colistin resistance was accumulated in colistin-
resistant E. coli. It is notable that along with PEA mod-
ification of the bacterial cell membrane lipid A, mcr-1 has
an effect on the biosynthesis and transport of lipoprotein in
colistin resistance through disrupting the expression of
efflux pump proteins that play a role in the resistance
pathway of cationic antimicrobial peptide (CAMP).
There is an association between the low intracellular c-di-
GMP level in dispersed cells of a P. aeruginosa strain and
a higher abundance of proteins required by the virulence
and development of antimicrobial peptide resistance in
P. aeruginosa.168 Therefore, P. aeruginosa cells with low
c-di-GMP levels act as an extra immunity to colistin than
P. aeruginosa cells with high c-di-GMP levels.
Antimicrobial
A polypeptide known as antimicrobial peptides (AMPs) is
generated endogenously to defend the host against micro-
bial invasion. Also, they function actively against a wide
range of microorganisms such as MDR bacteria.169 The
bacterium, in Vibrio parahaemolyticus, reacts to AMPs by
up-regulating the efflux channel, increasing the energy
consumption performance, repairing damaged membranes
effectively, and down-regulating of carbohydrate and
nucleotide metabolism to preserve energy.170 In the case
of Mycoplasma pulmonis, we know that the activation of
the stress response, which also triggers mutations in the
hrcA gene, can improve the development of resistance to
AMPs like melittin or gramicidin D.171 Furthermore, 2-DE
analyses, in M. pulmonis, indicated the up-regulation of
enzymes playing a role in energy metabolism as a feasible
outcome of the increased energy demand of the resistant
strains.172 Proteins that are effective in Vibrio parahaemo-
lyticus AMP resistance were indicated by Shen et al.173 In
addition, subculture of V.parahaemolyticus strains exposed
to four different AMPs demonstrated resistant strains.
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Additionally, two OMPs (TolC, flagellin) and five IMPs
(transcription termination factor NusA, EF-Tu, ATP
synthase α subunit, dihydrolipoamide dehydrogenase,
long-chain FA transport protein, FadL) were spotted by
analyses, which had changed the expression between the
WT and AMP-resistant strain significantly. Moreover, it is
believed that up-regulation of the energy-dependent MDR
efflux transporter (TolC and F1-ATPa), repair of damaged
membranes effectively (DLD) and AMPs cellular penetra-
tion (down-regulation of FadL)174 mediate AMP resis-
tance. These findings showed that the upregulation of the
TolC pump is a form of probable resistance mechanism
described with different antibiotics.
Polymyxins
As well-established antibiotics, Polymyxins have lately
drawn a great deal of attention as a result of the growing
incidence of infections caused by multidrug-resistant
Gram-negative bacteria.175 The polymyxins that are pro-
duced by Bacillus polymyxa are a set of cyclic polypep-
tides that altering the permeability of the cytoplasmic
membrane176 to induce their effect. Based on MALDI-
TOF analysis of the lipid A extracted from RamA-
overexpressing strains of K. pneumoniae, RamA increases
colistin/polymyxin resistance levels.177 This increase was
done by RamA that is directly bound to lipid
A biosynthesis genes like lpxC that modifies the structure
of lipid A. A study showed that overexpression of a pagL-
specific sRNA, Sr006 increased pagL mRNA, lipid
A deacetylation, and polymyxin B resistance in
P. aeruginosa. It also revealed that a pagL knockout led
to a decrease in polymyxin B resistance.178 Thus, the fact
that PagL is upregulated in chlorhexidine-resistant
P. aeruginosa means that the resistance action mechanism
to chlorhexidine might be the same, partially, as of
polymyxins.
Protein Synthesis-Acting Antibiotics
Chloramphenicol
Chloramphenicol is a broad-spectrum antibiotic that plays
a role in the synthesis of mitochondrial protein.179 The
chloramphenicol functions through creating bounds to the
50S bacterial ribosomal subunit and inhibiting the synth-
esis of protein.142 Studies have explained resistance to
chloramphenicol as part of the presence of the chloram-
phenicol acetyltransferase (CAT), which is an enzyme that
inactivates the drug.180 Li et al181 found six outer mem-
brane proteins and one protein of the location was
unknown and in charge of chloramphenicol (CAP)-
resistant Escherichia coli and for survival in medium
with suddenly strong CAP treatment. The study argued
that 4 out of the 7 proteins, including OmpC, TolC,
OmpT, and OmpW, were notably changed and they could
be considered as potential targets for developing new
medicines against CAP-resistant E. coli. Therefore, anti-
bodies that acted against the known OM proteins were
utilized to show antibody-combating bacterial growth.182
As the results showed anti-TolC had highly significant
inhibition on bacterial growth in medium with CAP.
This highlights a potential novel method to treat infection
by antibiotic-resistant bacteria. Antibiotic resistance
mechanisms Burkholderia thailandensis were used to
examine SDS-PAGE coupled with LC nanoelectrospray
MS/MS.183 The resistance induced by the chloramphenicol
was effective with structurally unrelated antibiotics such as
quinolones and tetracyclines.184 In general, the results
showed that there was an association between the multi-
drug resistance phenotype, found in chloramphenicol-
resistant variants and the over-expression of two different
efflux pumps, which were able to expel antibiotics from
several families.
Linezolid
One of the oxazolidinone antibiotics for clinical treatment
of severe infections with resistance against Gram-positive
bacteria is Linezolid.185 Linezolid an oxazolidinone that
binds to the 23S rRNA (Ribosomal ribonucleic acid) and it
demonstrates different resistance mechanisms such as
a higher expression of ABC transporters, mutations in
23S rRNA, mutations in ribosomal proteins L3 and L4,
and mutations in an RNA methyltransferase.7 Voigt et al186
studied expressions of the protein in S. aureus after a short
exposure to MCB3681, a new quinolonyl-oxazolidinone
antibacterial. They tried to answer the question if
MCB3681 can influence the expression of proteins differ-
ent from those influenced by ciprofloxacin or linezolid.
Their findings indicated that the effect of MCB3681 on
the proteome signature of treated S. aureus cells was not
the same as ciprofloxacin or linezolid. Proteomic and
transcriptomic screening of linezolid indicated that it is
feasible to increase the metabolism and transport of carbo-
hydrates in like linezolid-resistant S. pneumoniae
mutants.187 That is, resistant strains overexpressed several
glycolytic proteins, enzymes, and transporters involved in
sugar metabolism.
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Tetracycline
Aaminoacyl tRNA binding to the mRNA-ribosome com-
plex can be inhibited by tetracycline.188 There are at least
three mechanisms that create cell resistance to tetracycline
including enzymatic inactivation of tetracycline, efflux,
and ribosomal protection.189 Yun et al190 utilized proteo-
mic techniques to examine the surface proteome of
A. baumannii DU202 outer membrane vesicles (OMV).
This surface is notable resistant to tetracycline, after imi-
penem treatment. They reported a higher OMV secretion
after exposure to imipenem treatment and an increase
cytotoxicity towards A549 human lung carcinoma cells.
The differential proteome of E. coli K12 BW25113
exposed to chlortetracycline stress was labeled using iso-
baric tags and quantitative proteomics technology for rela-
tive and absolute quantitation of the labeling (Lin et al191).
The role of ribosome protein complexes in the translation
process was improved in general in the presence of chlor-
tetracycline stress, which is a compensatory mechanism
created by the chlortetracycline effect on the ribosome.
Therefore, these findings give us deeper insights to
hypothesize the role of energy to guarantees cell survival.
It appears that they change their metabolism to achieve
a basic level of energy production and ensure their survival
in the presence of the stress caused by a harmful antibiotic
agent. This hypothesis can be the subject to future studies
on proteomics.
Aminoglycoside
Through blocking the small 16S subunit of the bacterial
ribosome, aminoglycoside antibiotic family can stop pro-
tein synthesis.192 We know three aminoglycoside resis-
tance mechanisms including lowered uptake or decreased
cell permeability, modification at the ribosomal binding
sites, and generation of aminoglycoside modifying
enzymes.193 Low levels of NarG and NarH and two ele-
ments of respiratory nitrate reductase (Nar) were found in
streptomycin, gentamicin, ceftazidime, tetracycline, and
nalidixic acid-resistant E. coli strains in a proteomic
study based on native/SDS-PAGE.194 The protein expres-
sion profiles of a high-level spectinomycin-resistant (clin-
ical isolate) and a susceptible (reference strain) Neisseria
gonorrhoeae treated by sub minimal inhibitory concentra-
tions (subMICs) of spectinomycin were compared by
Nabu et al.195 Both strains demonstrated overexpression
of 50S ribosomal protein L7/L12 which is a key element
for ribosomal translocation. This means that compensatory
mechanisms function might be in response to antibiotics
that inhibit protein synthesis. To create the effects of
gentamicin on the proteomes of aerobic and oxygen-
limited E. coli, Proteomics techniques are an options.196
In addition, protein involvement in kanamycin resistance
was reported in a proteomic and Western blotting study of
the E. coli K-12 outer membrane (OM). Zhang et al197
reported an increase of some OM proteins like Tolc, TsX,
and OstA, and a decrease of MipA, OmpA, FadL, and
OmpW OM proteins in the kanamycin-resistant E. coli
K-12 strain. They argued that MipA is a new OM protein
implicated in antibiotic resistance.
Macrolides
Macrolide antibiotics function through creating a reversible
bound to the P site on the subunit 23 S of the bacterial
ribosome.198 The main tool of bacterial to resist against
macrolides is through post-transcriptional methylation of
the 23S bacterial ribosomal RNA.199 Among experimental
types of acquired resistance are a generation of drug-
inactivating enzymes (esterases or kinases) and generation
of active ATP (Adenosine triphosphate)-dependent efflux
proteins that transport the drug outside of the cell.200
Cash et al201 studies the proteins synthesized by erythromy-
cin-susceptible and erythromycin-resistant S. pneumoniae
using peptide mass mapping to find a 38500 Dalton protein
upregulated in resistant strains as glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH). Assuming that this
a probable reason for the resistance against erythromycin,
the authors maintained that was an increase in energy
production for the efflux system. Smiley et al202 conducted
a proteomic study on isolated sarcosine- insoluble outer
membrane protein (OMP) fractions obtained from clarithro-
mycin-susceptible and resistant Helicobacter pylori strains.
They demonstrated a decrease in iron-regulated membrane
protein, UreaseB, EF-Tu, and putative OMP; and an
increase in the HopT (BabB) transmembrane protein,
HofC, and OMP31 in clarithromycin-resistant H. pylori.
These findings indicate changing the outer membrane pro-
tein profile can be considered as a new mechanism effective
in clarithromycin resistance in H. pylori.
DNA Synthesis-Acting Antibiotics
Fluoroquinolones
A commonly used family of quinolones in clinical settings
is Fluoroquinolones.203 Quinolones inhibit the essential bac-
terial enzymes DNA gyrase and DNA topoisomerase IV.204
There are three quinolones resistance mechanism namely
mutations that change the drug targets, mutations that lower
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drug accumulation and plasmids that defend cells against
the lethal effects of quinolones.205 Proteomic studies on
protein expression levels have found 43 proteins with
higher expression in Salmonella enterica serovar
Typhimurium strains when a fluoroquinolone is added to
the bacterial culture.206 This means that the majority of
these proteins were only a physiological reaction to fluor-
oquinolone; still, there was an association between the
identified over-expressed AcrAB/TolC efflux pump and
resistance. Proteomic analyses are conducted to examine
the mechanisms at the protein level that confer resistance
to fluoroquinolones. A comparison between the proteomes
of fluoroquinolone-susceptible Coxiella burnetii and fluor-
oquinolone-resistant samples of the bacterium was done by
Vranakis et al.207 They showed diverse expressions of 15
bacterial proteins that had a role in different cellular pro-
cesses, which indicate the multifaceted feature of the anti-
biotic resistance mechanism in the bacterium. Additionally,
Lin et al208 showed an increase in the OM proteins TolC,
OmpT, OmpC, and OmpW and a decrease in FadL in the
nalidixic acid-resistant E. coli strains. Generally, TolC and
OmpC can have a stronger role in controlling nalidixic acid
resistance comparing with the other identified outer mem-
brane proteins.
Metronidazole
To inhibit nucleic acid synthesis, Metronidazole, as an
antibiotic of the nitroimidazole class, disrupts the DNA of
microbial cells.209 A study on the protein profiles of
a derivative of Helicobacter pylori strain 26695, featured
with resistance to moderate levels of metronidazole, showed
that the mutant strain improved the production of the resis-
tant phenotype of different isoforms of alkyl hydroperoxide
reductase when exposed to metronidazole.210 A study on
a metronidazole-resistant strain derived from B. fragilis
ATCC 25285 indicated that the proteomic changes influ-
enced a wide range of metabolic proteins such as lactate
dehydrogenase and flavodoxin.147 Changes in the metabolic
pathway effective in pyruvate-ferredoxin oxidoreductase
has been also reported by a multidisciplinary analysis of
a non-toxigenic Clostridium difficile strain that was resistive
to metronidazole.211 Moreover, according to proteomic ana-
lysis, DNA repair proteins, putative nitroreductases and the
ferric uptake regulator are regulated in a NAP1 C. difficile
clinical isolate that is resistive to metronidazole.212 The
results mean that there can be an association between
a multi-factorial response and high-level metronidazole-
resistance in C. difficile, such as the probable roles of
altered iron metabolism and/or DNA repair.
RNA Synthesis-Acting Antibiotics
Rifampicin
By inhibiting bacterial DNA-dependent RNA polymerase,
rifampicin can inhibit bacterial DNA-dependent RNA
synthesis.213 Rifampicin resistance is rooted in mutations
that change the residues of the rifampicin binding site on
RNA polymerase, which also leads to a lower affinity for
rifampicin.214 The possible to map resistant mutations to
the rpoB gene, encoding RNA polymerase beta subunit.215
Neri et al216 reported different expressions of 23 proteins
in two rifampicin-resistant and one susceptible meningo-
coccus. Moreover, they report an increase in the proteins
involved in the major metabolic pathways such as pyru-
vate catabolism and the tricarboxylic acid cycle; still, they
showed a decrease in the proteins related to gene regula-
tion in polypeptide folding. Rifampicin-resistant in
a rifampicin resistant strain of Brucella abortus 2308
developed in vitro was analyzed by Sandalakis et al.217
The resistant strain indicated the described mutation
V154F, in the rpoB gene. Among 456 proteins found by
MS/MS, the resistant strain had 39 differentially affected
proteins that play a role in different metabolic pathways.
Moreover, rifampicin resistance in Brucella is mostly
effective in the excitation of many metabolic processes
and possible use of the secretion mechanisms that exist
at a more efficient level.218 In general, these results indi-
cate that rather than an outcome of changes in single
proteins, resistance is the outcome of a complicated cellu-
lar processes network.
Proteomics Methods to Provide
Mechanistic Insights in Bacterial
Virulence
Growingly, proteomic techniques are attracting attention
as key tools for studying bacterial pathogenesis.134 Uses of
these tools are finding of virulence factors and examining
the response of both host and pathogen to infection.
Provenzano et al219 studied the metaproteome of microbial
communities caused by endodontic infections featured
with severe apical abscesses and asymptomatic apical per-
iodontal lesions. They argued that many of the detected
human proteins had a role in cellular processes and meta-
bolism and immune defense. Wang et al220 compared the
proteome profile of the S. enterica subsp. enterica serovar
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Typhimurium and S. typhi. These profiles are in charge of
gastroenteritis and typhoid fever types. The authors first
found a set of proteins with the serovar-specific expression
as a novel biomarkers for finding clinical serotypes. They
also reported that compared with S. typhimurium, the
expression of flagella and chemotaxis proteins was lower
in S. typhi. Mirrashidi et al131 employed affinities purifica-
tion-mass spectroscopy to find Inc-human interactions for
38/58 Incs that plays a role in intracellular life cycles of
the host, including retromer components as sorting nexin.
Observation of inc targets and overlapping of viral pro-
teins indicates common pathogenic mechanisms among
obligate intracellular microbes. In general, the findings
mean that a better understanding of virulence factors and
resistance mechanisms to antibiotics is achievable through
realizing the functionalities of the involved proteins.
Conclusion
Using proteomic analysis gives us a valuable systematic
approach to study the protein complement of bacterial
pathogenesis. However, studies on using proteomic analy-
sis to examine the interactions between bacterial pathogen-
esis and host are at early stages. That is, the new frontline
of studies on pathogens is at the interface between the
pathogen and host and examining the interaction of viru-
lence proteins with cognate host entities, coordination of
their actions, and finally subverting the host cell function
as part of the disease process. However, we can use
systems-level proteomic analyses to examine the intrinsi-
cally delicate balance of host-pathogen interactions. In
addition, the host cells possess many defense strategies
to defend against and kill invading pathogens. These key
aspects of host-pathogen interactions are visible in proteo-
mic differences. Research works on human infectious dis-
eases have been extended notably thanks to proteomic
approaches to pathogenic research. Proteomic tools are
becoming promising ways for clinical studies and diagno-
sis. In another word, these proteomic studies have led to
discoveries about different pathogenic infections by study-
ing pathogenic factors, host anti-pathogen proteins, and
protein complexes and profiling host and pathogen PTM
sites during infection. The convergence of proteomics and
omic technologies provides chances to have a clearer pic-
ture of the dynamics of diseases and find therapeutic
targets. There is an immense potential for proteomic stu-
dies on PTMs to uncover mechanisms that mediate the
progression, spread, and pathogenicity of infection.
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